Daniel F Hayes Selected Research

Estradiol (Delestrogen)

3/2022	Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models.
1/2017	Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer.
5/2012	Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Daniel F Hayes Research Topics

Disease

196	Breast Neoplasms (Breast Cancer) 01/2024 - 02/2002
103	Neoplasms (Cancer) 01/2024 - 02/2002
19	Circulating Neoplastic Cells 01/2024 - 03/2005
12	Neoplasm Metastasis (Metastasis) 10/2023 - 08/2003
8	Pain (Aches) 10/2022 - 09/2008
7	Peripheral Nervous System Diseases (PNS Diseases) 01/2022 - 01/2018
7	Hot Flashes 11/2015 - 04/2002
6	Prostatic Neoplasms (Prostate Cancer) 01/2020 - 02/2003
5	Triple Negative Breast Neoplasms 01/2023 - 12/2016
5	Leukemia 08/2011 - 02/2002
3	Carcinoma (Carcinomatosis) 04/2021 - 05/2014
3	Cognitive Dysfunction 10/2020 - 09/2014
3	Pathologic Complete Response 10/2019 - 08/2005
3	Disease Progression 01/2016 - 07/2006
3	Germ Cell and Embryonal Neoplasms (Germ Cell Tumor) 07/2010 - 12/2008
3	Colorectal Neoplasms (Colorectal Cancer) 04/2009 - 11/2006
2	Neutropenia 01/2023 - 11/2010
2	Microsatellite Instability 11/2022 - 11/2006
2	Osteonecrosis (Kienbock's Disease) 01/2022 - 01/2020
2	Noninfiltrating Intraductal Carcinoma (DCIS) 01/2020 - 01/2020
2	Second Primary Neoplasms (Neoplasms, Second) 07/2018 - 01/2013
2	Cardiovascular Diseases (Cardiovascular Disease) 03/2016 - 02/2012
2	Syndrome (Syndromes) 01/2016 - 08/2014
2	Fatigue 09/2014 - 08/2014
2	Chronic Pain 05/2014 - 12/2011
2	Lung Neoplasms (Lung Cancer) 10/2013 - 11/2011
2	Colonic Neoplasms (Colon Cancer) 11/2011 - 11/2006
1	Thrombocytopenia (Thrombopenia) 01/2023

Drug/Important Bio-Agent (IBA)

43	Hormones (Hormone)IBA 10/2022 - 02/2003
37	Estrogen ReceptorsIBA 10/2023 - 03/2003
33	Biomarkers (Surrogate Marker)IBA 01/2024 - 11/2004
24	Tumor Biomarkers (Tumor Markers)IBA 01/2024 - 03/2005
22	Tamoxifen FDA LinkGeneric 03/2022 - 02/2002
21	Aromatase InhibitorsIBA 01/2024 - 09/2006
20	Proteins (Proteins, Gene)FDA Link 01/2023 - 01/2003
19	Estrogens (Estrogen)FDA Link 03/2022 - 12/2008
17	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2023 - 02/2002
16	Letrozole (Femara)FDA LinkGeneric 10/2022 - 09/2008
16	exemestane (Aromasin)FDA Link 10/2022 - 09/2008
16	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2019 - 02/2002
14	Progesterone Receptors (Progesterone Receptor)IBA 10/2023 - 12/2008
14	Paclitaxel (Taxol)FDA LinkGeneric 01/2022 - 01/2003
13	human ERBB2 proteinIBA 10/2023 - 01/2007
9	DNA (Deoxyribonucleic Acid)IBA 04/2021 - 04/2006
9	Cytochrome P-450 CYP2D6 (CYP2D6)IBA 09/2013 - 12/2003
7	Circulating Tumor DNAIBA 01/2024 - 10/2017
7	AnthracyclinesIBA 09/2023 - 06/2002
7	ErbB Receptors (EGF Receptor)IBA 11/2022 - 10/2007
7	Fulvestrant (Faslodex)FDA Link 03/2022 - 08/2012
6	Anastrozole (Arimidex)FDA LinkGeneric 01/2022 - 03/2012
6	RNA (Ribonucleic Acid)IBA 04/2021 - 05/2002
6	ParaffinIBA 12/2019 - 08/2011
5	Formaldehyde (Formol)FDA Link 12/2019 - 08/2011
5	Fluorouracil (Carac)FDA LinkGeneric 01/2019 - 02/2002
4	taxaneIBA 10/2022 - 12/2011
4	Capecitabine (Xeloda)FDA Link 01/2012 - 07/2006
3	Estradiol (Delestrogen)FDA LinkGeneric 03/2022 - 05/2012
3	AZD9496IBA 03/2022 - 12/2018
3	Bevacizumab (Avastin)FDA Link 01/2022 - 12/2007
3	LigandsIBA 04/2020 - 12/2018
3	Trastuzumab (Herceptin)FDA Link 11/2017 - 12/2008
3	ametantrone (HAQ)IBA 07/2017 - 09/2008
3	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 11/2015 - 02/2003
3	Carcinoembryonic AntigenIBA 08/2015 - 11/2006
2	Immunoconjugates (Immunoconjugate)IBA 01/2023 - 01/2023
2	Everolimus FDA Link 01/2022 - 01/2013
2	Diphosphonates (Bisphosphonates)IBA 01/2022 - 01/2020
2	Zoledronic Acid (Zometa)FDA Link 01/2022 - 01/2020
2	Monoclonal AntibodiesIBA 01/2021 - 04/2009
2	Immune Checkpoint InhibitorsIBA 01/2021 - 01/2018
2	B7-H1 AntigenIBA 01/2021 - 01/2018
2	Androgen Receptors (Androgen Receptor)IBA 01/2017 - 07/2003
2	Phosphotransferases (Kinase)IBA 12/2016 - 01/2016
2	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 04/2016 - 12/2008
2	Plasminogen Activators (Plasminogen Activator)IBA 04/2016 - 12/2008
2	LipidsIBA 03/2016 - 12/2012
2	Progesterone FDA LinkGeneric 01/2016 - 05/2015
2	Docetaxel (Taxotere)FDA Link 03/2013 - 07/2007
2	4-hydroxy-N-desmethyltamoxifenIBA 03/2012 - 07/2006
2	Serotonin (5 Hydroxytryptamine)IBA 12/2011 - 04/2002
2	AntibodiesIBA 08/2011 - 06/2009
2	EnzymesIBA 11/2010 - 01/2005
2	Prostate-Specific Antigen (Semenogelase)IBA 12/2008 - 02/2003
2	Cyclin EIBA 11/2007 - 12/2006
2	Thymidine PhosphorylaseIBA 07/2007 - 11/2006
2	Paroxetine (Paxil)FDA LinkGeneric 10/2005 - 12/2003
2	Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)IBA 01/2005 - 12/2003

Therapy/Procedure

100	Therapeutics 05/2023 - 04/2002
46	Drug Therapy (Chemotherapy) 01/2024 - 01/2003
23	Adjuvant Chemotherapy 01/2021 - 06/2002
7	Neoadjuvant Therapy 10/2019 - 04/2002
6	Radiotherapy 01/2020 - 04/2002
5	Precision Medicine 01/2023 - 01/2014
4	Lymph Node Excision (Lymph Node Dissection) 10/2007 - 04/2002
3	Aftercare (After-Treatment) 11/2017 - 12/2006
2	Time-to-Treatment 10/2022 - 01/2006
2	Mastectomy (Mammectomy) 05/2015 - 09/2009
2	Chemoprevention 02/2010 - 11/2004
2	Segmental Mastectomy (Lumpectomy) 09/2009 - 04/2002
1	Polypharmacy 01/2024